U.S. Markets closed

Rexahn Pharmaceuticals, Inc. (RNN)

NYSE MKT - NYSE MKT Delayed Price. Currency in USD
Add to watchlist
1.92-0.03 (-1.54%)
At close: 4:00PM EDT

1.91 -0.01 (-0.52%)
After hours: 4:14PM EDT

People also watch
MSTXGALEAEZSIMUCINO
Full screen
Previous Close1.95
Open1.96
Bid1.91 x 300
Ask1.96 x 1500
Day's Range1.91 - 1.96
52 Week Range0.13 - 4.74
Volume35,470
Avg. Volume254,020
Market Cap54.64M
Beta0.10
PE Ratio (TTM)-1.62
EPS (TTM)N/A
Earnings DateN/A
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Associated Press10 days ago

    Rexahn posts 2Q profit

    The Rockville, Maryland-based company said it had net income of 3 cents per share. Losses, adjusted for non-recurring gains, were 17 cents per share. The company's shares closed at $1.84. A year ago, they ...

  • Rodman & Renshaw Encouraged on Rexahn Pharmaceuticals, Inc. (RNN) Following ASCO Update
    SmarterAnalyst2 months ago

    Rodman & Renshaw Encouraged on Rexahn Pharmaceuticals, Inc. (RNN) Following ASCO Update

    Rexahn Pharmaceuticals, Inc. (NYSEMKT:RNN) offered a key glimpse into its advanced muscle invasive bladder cancer (MIBC) Phase 2a trial  at the American Society of Clinical Oncology conference over the weekend. In reaction, Rodman & Renshaw Joseph Pantginis sees beneficial opportunity for bladder cancer patients and is bullish on the firm's pipeline drug, reiterating a Buy rating on shares of RNN with a $19.50 price target, which represents a 391% increase from current levels.

  • Associated Press3 months ago

    Rexahn reports 1Q loss

    The Rockville, Maryland-based company said it had a loss of 9 cents per share. Losses, adjusted for non-recurring costs, were 2 cents per share. The company's shares closed at 40 cents. A year ago, they ...